ReviewCancer innovation2026
Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025.
Review in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rapid advancement of molecular profiling and precision therapeutics, targeted and immunotherapeutic strategies have irrevocably reshaped the pharmacological management for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Overall mortality from lung cancer has continued its downward trend over the past decade, and this decline has accelerated, largely driven by advances in early detection and curative-intent surgeries. In parallel, the systemic therapies have undergone a dramatic evolution with the integration of, for example, antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs). The year 2025 marks a period of significant progress in lung cancer treatment, characterized by groundbreaking therapeutic successes across all disease stages and subtypes. This comprehensive review synthesizes pivotal evidence presented at key oncology forums in 2025 to delineate the substantially evolved clinical landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.